MEDICAL COVERAGE POLICY SERVICE: Xofigo SERVICE: PRIOR - SWHP
SERVICE: Xofigo MEDICAL COVERAGE POLICY Policy Number: 212 Effective Date: 03/06/2015 Last Review: 02/12/2015 Next Review Date: 02/12/2016 Xofigo Page Xofigo is used to treat patients with prostate cancer that is resistant to standard medical or surgical ... View Doc
Xofigo Informed Consent - GwinnettMD
PATIENT NAME: _____ DATE: _____ TIME: _____ The diagnosis requiring this procedure is: Castration-resistant (cancer that is no longer responding to hormone therapy) prostate cancer with metastases to the bone. ... Access This Document
Precision Radiation Treatment With Xofigo - Medical Minute ...
Gary Seitz has been a fighter. His opponent? Prostate cancer. His tag team partner? Xofigo ... View Video
Approval Criteria Department Of Pharmacy Services
Brand Name: Xofigo® Medication Class: Radiotherapeutic FDA Approved Uses Prostate Cancer: For treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. ... Read Content
Radium Ra 223 Dichloride Injection For Prostate Cancer ...
Output while being treated with Xofigo. They should be instructed to report signs of dehydration, hypovolemia, According to the American Cancer Society, prostate cancer is the most frequently diagnosed cancer aside ... Read Full Source
Tri-City Medical Center Adds To Its Arsenal In The Treatment ...
According to the American Cancer Society, prostate cancer remains the leading cancer type among men outside of skin cancer, and about one man in every six will develop the illness ... Return Document
UNIFORM PHARMACY PRIOR AUTHORIZATION REQUEST FORM - Rmhp.org
UNIFORM PHARMACY PRIOR AUTHORIZATION REQUEST FORM Castration-resistant prostate cancer with symptomatic BONE metastases and NO visceral metastases Other (please state): Xofigo® (radium Ra 223 dichloride [radium 223]) ... Access Content
Available By Prescription Only. - xofigo-us.com
Xofigo is used to treat prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has spread to your bones with symptoms, but not to other parts of your body Before taking Xofigo, tell your healthcare provider if you: ... Retrieve Here
TO WHOM IT MAY CONCERN Radium 223 (Xofigo) For The Treatment ...
MSAC Secretariat . Department of Health . MDP 853 . GPO 9848 Canberra ACT 2601 . TO WHOM IT MAY CONCERN . Radium 223 (Xofigo) for the treatment of patients with symptomatic castrate resistant prostate ... Access Full Source
MEDICAL POLICY LAST REVIEW . . . Radium Ra-223 Dichloride ...
Radium Ra-223 dichloride (Xofigo®) GUIDELINES This policy does not certify benefits or authorization of benefits, treatment of patients with castrate-resistant prostate cancer (CRPC) with symptomatic bone metastases, and no visceral metastases. ... Fetch Here
Prostate Cancer Foundation - Wikipedia, The Free Encyclopedia
History. The Prostate Cancer Foundation, formerly known as CaP CURE, was founded in 1993 by Michael Milken following his personal battle with prostate cancer. ... Read Article
Radium-223 - Wikipedia, The Free Encyclopedia
Radium-223 (Ra-223, 223 Ra) is an isotope of radium with an 11.4-day half-life, (FDA) [9] as a treatment for castration-resistant prostate cancer (CRPC) with bone metastases in patients with symptomatic bone metastases and without known visceral disease. ... Read Article
Radium-223 Dichloride (Xofigo®) Injectable Medication ...
Request is for Xofigo Dose: Frequency: F Yes No Does the patient have clinical evidence of metastasis from prostate cancer? If yes, Injectable Medication Precertification Request Keywords: Radium-223 Dichloride Xofigo ... Document Retrieval
Mississauga, ON L4W 5R6 News Release - Bayer.ca
Metastases as a result of metastatic castration resistant prostate cancer Bayer introduces Xofigo, a novel treatment for prostate cancer, now publicly funded for patients in Ontario TORONTO, ON, March 9, 2015 – Bayer Inc. announces today the availability of Xofigo (radium ... Retrieve Document
Administration Guide - Hcp.xofigo-us.com
INDICATION Xofigo® is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. ... Retrieve Document
Medication Policy Manual Policy No: Date Of Origin
Radium Ra 223 dichloride ( Xofigo) is an intravenously injected radiotherapy used in the treatment of castration-resistant prostate cancer in patients with symptomatic bone ... Access Content
3. How Xofigo Is Used - Medicines
Xofigo is used to treat adults with advanced castration-resistant prostate cancer. This is a cancer of the prostate No cases of Xofigo-induced cancer have been reported in clinical trials in follow-up of up to three years. ... Doc Viewer
1 Licensing Decision PAGE For Radium-223 Dichloride
FOR RADIUM-223 . DICHLORIDE . PAGE . 1. UPDATE ON . REVISIONS TO THE RADIATION PROTECTION REGULATIONS . PAGE . 2. FROM THE . DESK OF THE DIRECTOR . PAGE . 3. of skeletal metastases in advanced castration-resistant prostate cancer. Radium-223 naturally self-targets bone metastases by ... Retrieve Content
Bone Metastasis - Wikipedia, The Free Encyclopedia
Bone is the third most common location for metastasis, after the lung and liver. [5] While any type of cancer is capable of forming metastatic tumors within bone, the microenvironment of the marrow tends to favor particular types of cancer, including prostate, breast, and lung cancers. [3] ... Read Article
Xofigo, INN Radium-223 Chloride - Ministry Of Health
Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. 4.2 Posology and method of administration ... Fetch Here
SUM-XOFIGO (radium Ra 223 Dichloride) 9 - SummaCare
Xofigo® PA Criteria September 5, 2013 XOFIGO® (radium Ra 223 dichloride) Criteria for Coverage – Commercial Enrollees only The patient has diagnosis of castration-resistant prostate cancer; AND 2) The patient has symptomatic bone metastases; ... Read Document
Xofigo Radioactive Therapeutic Agent - UnitedHealthcare Online
Xofigo Radioactive Therapeutic Agent Xofigo® (radium Ra 223 dichloride) injection is an alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), ... Document Viewer
News Release - AMP
News Release - 1/1 - Intended for U.S. Media Only Whippany, NJ, thousands of patients have received Xofigo at cancer treatment centers across the country, Prostate cancer is the most common cancer among men in the United States ... View Full Source
Starting Treatment Early For Metastatic Prostate Cancer: Part III
Doctors use excessively conservative thinking for many reasons and don't always evaluate “outside the box,” treatment approaches. ... Read Article
How Do You Know If Xofigo For Prostate Cancer Is Working ...
Xofigo for prostate cancer is a radiation treatment option for patients with aggressive cancer that has spread to the bones. These cases are generally where hormone reduction therapy has proven ineffective. ... View Video
Who Is Considered A Candidate For Xofigo For Prostate Cancer?
Xofigo for prostate cancer is a relatively new treatment method for men with aggressive prostate cancer that has spread to the bones. Xofigo works by bonding with minerals in the bones to distribute radiation. ... View Video
No comments:
Post a Comment